Tag: Bio-Path Holdings

August 26, 2019

Bio-Path Doses Patient in Amended Phase 2 Prexigebersen Trial

Bio-Path Holdings (NASDAQ:BPTH) has announced patient dosing in its amended Phase 2 trial of prexigebersen to treat acute myeloid leukemia...